Drug-induced cholestasis

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 519-531

  Bhamidimarri, Kalyan Ram ^a   Schiff, Eugene ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Bile duct injury; Cholestasis; Drugs; Liver injury; Management

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANABOLIC AGENT; ANTIHISTAMINIC AGENT; AZITHROMYCIN; CARBENICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOXACILLIN; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; DOXYCYCLINE; ESTROGEN; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; STAVUDINE; SULFONAMIDE; TELITHROMYCIN; TEMAFLOXACIN; TICARCILLIN; TIGECYCLINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE CHOLESTATIC DRUG INDUCED LIVER INJURY; ACUTE LIVER FAILURE; ANTIOXIDANT ACTIVITY; CHOLELITHIASIS; CHOLESTASIS; CHRONIC CHOLESTATIC DRUG INDUCED LIVER INJURY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED CHOLESTASIS; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ECHOGRAPHY; ELECTRON MICROSCOPY; ENTEROHEPATIC CIRCULATION; GENETIC ASSOCIATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAHEPATIC CHOLESTASIS; LIVER CIRRHOSIS; LIVER GRAFT; LIVER INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PROGNOSIS; PRURITUS; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

BILE DUCT INJURY; CHOLESTASIS; DRUGS; LIVER INJURY; MANAGEMENT;

CHOLESTASIS; DRUG-INDUCED LIVER INJURY; HUMANS; RISK FACTORS;

EID: 84884947976     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.015     Document Type: Review

References (59)

1. Siddique A., Kowdley K.V. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis 2012, 16(2):199-229.
2. Ghabril M., Chalasani N., Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol 2010, 26(3):222-226.
3. Degott C. Drug-induced liver injury. Cholestatic injury, acute and chronic. Pathol Oncol Res 1997, 3(4):260-263.
4. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008, 14(44):6774-6785.
5. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. NEngl J Med 2006, 354(7):731-739.
6. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137(12):947-954.
7. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36(2):451-455.
8. Bjornsson E.S., Jonasson J.G. Drug-induced cholestasis. Clin Liver Dis 2013, 17(2):191-209.
9. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135(6):1924-1934. 1934.e1-4.
10. Lucena M.I., Andrade R.J., Kaplowitz N., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009, 49(6):2001-2009.
11. Andrade R.J., Lucena M.I., Fernández M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129(2):512-521.
12. Daly A.K., Donaldson P.T., Bhatnagar P., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41(7):816-819.
13. Andrade R.J., Lucena M.I., Alonso A., et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004, 39(6):1603-1612.
14. Meier Y., Zodan T., Lang C., et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008, 14(1):38-45.
15. Lammert C., Bjornsson E., Niklasson A., et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51(2):615-620.
16. Mancinelli R., Onori P., Demorrow S., et al. Role of sex hormones in the modulation of cholangiocyte function. World J Gastrointest Pathophysiol 2010, 1(2):50-62.
17. Pauli-Magnus C., Meier P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006, 44(4):778-787.
18. Lang C., Meier Y., Stieger B., et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007, 17(1):47-60.
19. Velayudham L.S., Farrell G.C. Drug-induced cholestasis. Expert Opin Drug Saf 2003, 2(3):287-304.
20. Teschke R., Schwarzenboeck A., Hennermann K.H. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008, 66(6):758-766.
21. Suk K.T., Kim D.J. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012, 18(3):249-257.
22. Garcia Rodriguez L.A., Stricker B.H., Zimmerman H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996, 156(12):1327-1332.
23. Hussaini S.H., O'Brien C.S., Despott E.J., et al. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007, 19(1):15-20.
24. Lucena M.I., Andrade R.J., Fernández M.C., et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006, 44(4):850-856.
25. Fontana R.J., Shakil A.O., Greenson J.K., et al. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005, 50(10):1785-1790.
26. Olsson R., Wiholm B.E., Sand C., et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. JHepatol 1992, 15(1-2):154-161.
27. de Abajo F.J., Montero D., Madurga M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004, 58(1):71-80.
28. Turner I.B., Eckstein R.P., Riley J.W., et al. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989, 151(11-12):701-705.
29. Davies M.H., Harrison R.F., Elias E., et al. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. JHepatol 1994, 20(1):112-116.
30. Andrade R.J., Guilarte J., Salmerón F.J., et al. Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother 2001, 35(6):783-784.
31. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. JAntimicrob Chemother 2011, 66(7):1431-1446.
32. Derby L.E., Jick H., Henry D.A., et al. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993, 158(9):600-602.
33. Lockwood A.M., Cole S., Rabinovich M. Azithromycin-induced liver injury. Am J Health Syst Pharm 2010, 67(10):810-814.
34. Brinker A.D., Wassel R.T., Lyndly J., et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009, 49(1):250-257.
35. Lucena M.I., Andrade R.J., Rodrigo L., et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000, 30(2):400-401.
36. Gupta A.K., del Rosso J.Q., Lynde C.W., et al. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998, 23(2):64-67.
37. Agarwal K., Manas D.M., Hudson M. Terbinafine and fulminant hepatic failure. NEngl J Med 1999, 340(16):1292-1293.
38. Yoshikado T., Takada T., Yamamoto T., et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011, 79(2):241-250.
39. Akhtar A.J., Shaheen M. Jaundice in African-American and Hispanic patients with AIDS. JNatl Med Assoc 2007, 99(12):1381-1385.
40. Bjornsson E., Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006, 38(1):33-38.
41. Cachay E.R., Peterson M.R., Goicoechea M., et al. Didanosine exposure and noncirrhotic portal hypertension in an HIV clinic in North America: a follow-up study. Br J Med Med Res 2011, 1(4):346-355.
42. Kovari H., Ledergerber B., Peter U., et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009, 49(4):626-635.
43. Levy C., Lindor K.D. Drug-induced cholestasis. Clin Liver Dis 2003, 7(2):311-330.
44. Bastida G., Nos P., Aguas M., et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005, 22(9):775-782.
45. Gisbert J.P., Gonzalez-Lama Y., Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007, 102(7):1518-1527.
46. Roda G., Caponi A., Belluzzi A., et al. Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis. Dig Liver Dis 2009, 41(12):914-915.
47. Moradpour D., Altorfer J., Flury R., et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994, 20(6):1437-1441.
48. Lammert C., Einarsson S., Saha C., et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47(6):2003-2009.
49. Vuppalanchi R., Hayashi P.H., Chalasani N., et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010, 32(9):1174-1183.
50. Clarke J.D., Cherrington N.J. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol 2012, 8(3):349-360.
51. Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis 2009, 29(4):364-372.
52. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. JClin Pathol 2009, 62(6):481-492.
53. Vuppalanchi R., Chalasani N., Saxena R. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol 2006, 30(12):1619-1623.
54. Perez M.J., Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009, 15(14):1677-1689.
55. Decock S., Roelandts R., Steenbergen W.V., et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. JHepatol 2012, 57(3):637-641.
56. Herrero-Herrero J.I., Garcia-Aparicio J. Corticosteroid therapy in a case of severe cholestatic hepatitis associated with amoxicillin-clavulanate. JMed Toxicol 2010, 6(4):420-423.
57. Geubel A.P., Sempoux C.L. Drug and toxin-induced bile duct disorders. JGastroenterol Hepatol 2000, 15(11):1232-1238.
58. Lewis J.H., Zimmerman H.J. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999, 3(3):433-464. vii.
59. Andrade R.J., Lucena M.I., Kaplowitz N., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44(6):1581-1588.